46 96

Cited 0 times in

Impact of amlodipine on clinical outcomes for heart failure in patients with dilated cardiomyopathy: a Korean nationwide cohort study

Authors
 SungA Bae  ;  Wan Kee Kim  ;  Seng Chan You  ;  Minkwan Kim  ;  In Hyun Jung 
Citation
 FRONTIERS IN CARDIOVASCULAR MEDICINE, Vol.10 : 1305824, 2023-11 
Journal Title
FRONTIERS IN CARDIOVASCULAR MEDICINE
Issue Date
2023-11
Keywords
all-cause death ; amlodipine ; dilated cardiomyopathy ; heart failure ; hospitalization ; hypertension ; hypertension age ; sex
Abstract
Introduction: Amlodipine, widely used as a first-line treatment for hypertension, has inconclusive clinical evidence regarding its efficacy in patients with heart failure. This retrospective cohort study aimed to investigate the clinical effectiveness of amlodipine treatment after hospitalization for heart failure in patients with dilated cardiomyopathy (DCMP).

Methods: A total of 20,851 patients who were diagnosed with DCMP and admitted for heart failure between 2005 and 2016 according to Korean nationwide medical insurance service database were enrolled. Amlodipine use was defined as its prescription at the time of discharge and for at least 180 days within a year. The primary outcome was all-cause death, and the secondary outcome was heart failure rehospitalization during a 5-year period. The outcomes between patients who received amlodipine (n = 6,798) and those who did not (n = 14,053) were compared.

Results: During the 5-year follow-up, the group treated with amlodipine exhibited a significantly lower risk of all-cause death and heart failure rehospitalization than the group not treated with amlodipine [all-cause death: adjusted hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.59-0.70, p < 0.001; cardiovascular death: adjusted HR: 0.71, 95% CI: 0.62-0.81, p < 0.001; heart failure rehospitalization: adjusted HR: 0.92, 95% CI: 0.86-0.98, p = 0.006]. In a subgroup analysis, amlodipine had a significant impact on decreasing all-cause mortality in older adults, those with a higher systolic blood pressure, and those with a lower Charlson Comorbidity Index.

Conclusion: In summary, amlodipine use after hospitalization for heart failure in patients with DCMP was associated with a lower risk of all-cause death and readmission for heart failure.
Files in This Item:
T202306599.pdf Download
DOI
10.3389/fcvm.2023.1305824
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Minkwan(김민관) ORCID logo https://orcid.org/0000-0002-4079-8219
Bae, SungA(배성아) ORCID logo https://orcid.org/0000-0003-1484-4645
You, Seng Chan(유승찬) ORCID logo https://orcid.org/0000-0002-5052-6399
Jung, In Hyun(정인현) ORCID logo https://orcid.org/0000-0002-1793-215X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/197338
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links